Secures $50.0 Million Credit Facility with K2 HealthVentures
Summary
We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders.MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.K2 HealthVentures is an alternative investment firm focused on providing flexible, long-term financing solutions to innovative private and public companies in the life sciences and healthcare industries. The investment team comprises collaborative, experienced professionals with diverse backgrounds in finance and operations, as well as deep domain knowledge across various healthcare sectors. These statements generally can be identified by the use of forward-looking words such as will, may, should, could, intend, estimate, plan, anticipate, expect, believe, potential or continue, or the negative thereof or similar variations. Although management of the Company considers these assumptions to be reasonable based on information currently available to it, they may prove to be incorrect.There are numerous risks and uncertainties that could cause actual results and the Companys plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; changes in market conditions; lack of product revenue; compliance with laws and regulations; changes in government policy; difficulty associated with research and development; risks associated with clinical trials or studies; heightened regulatory scrutiny; early stage product development; clinical trial risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; as well as those risk factors discussed or referred to herein and the risks described in the Companys Annual Report on Form 10-K for the fiscal year ended December 31, 2022, the Companys Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2023 under headings such as Special Note Regarding Forward-Looking Statements, and Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations and other filings and furnishings made by the Company with the securities regulatory authorities in all provinces and territories of Canada which are available under the Companys profile on SEDAR at www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events, changes in expectations or otherwise.